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Abstract
Background: Intensification of metformin monotherapy with additional glucose-lowering drugs is often required in
patients with type 2 diabetes (T2D). This study evaluated changes in HbA1c and weight, as well as treatment
persistence, associated with different second-line therapies used in UK clinical practice.
Methods: The UK Clinical Practice Research Datalink was used to identify patients with T2D who initiated second-line
therapy after metformin monotherapy between 1 August 2013 and 14 June 2016. Treatment persistence and changes
in HbA1c and weight were assessed at 6-month intervals up to 18 months.
Results: In total, 9097 patients (mean age 61.2 years, 57.2% men, mean [standard deviation] HbA1c 9.0% [1.8]/
75 mmol/mol [19.7]) were included in the analysis, with a median 2.3 years between initiating metformin monotherapy
and initiating second-line therapy. Patients were stratified according to second-line therapy: metformin in combination
with sulfonylurea (SU; n = 4655 [51.2%]), a dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor; n = 2899 [31.9%]), or a
sodium–glucose cotransporter-2 inhibitor (SGLT-2 inhibitor; n = 441 [4.9%]) or other therapies (all other second-line
treatments; n = 1102 [12.1%]). At 18 months, the cumulative proportion of patients changing treatment was lowest for
those who received metformin plus an SGLT-2 inhibitor (42.3%), followed by patients on metformin plus SU or
metformin plus a DPP-4 inhibitor (46.8%). HbA1c reductions were seen with all second-line therapies, with an overall
mean (standard error) reduction of −1.23% (0.05)/−13.4 mmol/mol (0.5). Changes were directly, but not linearly, related
to baseline HbA1c and were greater in those with higher HbA1c at baseline. Weight loss from baseline was greatest in
patients treated with metformin plus either an SGLT-2 inhibitor (−4.2 kg) or a DPP-4 inhibitor (−1.5 kg). The highest
proportion of patients who achieved the composite outcome of HbA1c reduction ≥ 0.5%, body weight loss ≥ 2.0 kg
and treatment persistence for 18 months was observed in those receiving metformin plus an SGLT-2 inhibitor (36.5%).
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Conclusions: In this population-based cohort, all second-line therapies added to metformin monotherapy improved
glycaemic control, but the lowest treatment change/discontinuation rate and most sustained weight loss was seen
with patients receiving metformin plus an SGLT-2 inhibitor.
Keywords: Clinical practice research datalink (CPRD), Dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor), HbA1c,
Metformin, Second-line therapy, Sodium-glucose cotransporter 2 inhibitor (SGLT-2 inhibitor), Sulfonylurea,
Type 2 diabetes (T2D)
Background
Type 2 diabetes (T2D) is a complex chronic condition
characterised by increased blood glucose levels and asso-
ciated with micro- and macrovascular complications. In
2015, an estimated 415 million people globally had dia-
betes, with the vast majority (~ 90%) having T2D [1].
Optimal glycaemic control (i.e. attaining recommended
treatment targets) has been shown to reduce the inci-
dence of diabetes-related complications, microvascular
disease and myocardial infarction in the large, long-term
United Kingdom Prospective Diabetes Study [2, 3].
Along with lifestyle modifications, current guidelines
recommend the use of metformin as the preferred
first-line glucose-lowering therapy in patients with T2D
[4]. Metformin has a low risk of hypoglycaemia and is
weight neutral, with no increased risk of or benefit against
adverse cardiovascular events [5, 6]. However, in view of
its progressive nature, the majority of patients with T2D
require treatment intensification from metformin mono-
therapy to achieve and maintain recommended HbA1c
targets [6]. Second-line agents approved for dual therapy
with metformin in the UK include sulfonylureas (SUs),
thiazolidinediones (TZDs), dipeptidyl peptidase-4 (DPP-4)
inhibitors, sodium–glucose cotransporter-2 (SGLT-2)
inhibitors, glucagon-like peptide-1 (GLP-1) receptor ago-
nists and basal insulin analogues. The National Institute
for Health and Care Excellence (NICE) guidelines and the
position statement of the American Diabetes Association
and the European Association for the Study of Diabetes
recommend that initial treatment intensification after
failure of metformin monotherapy should consist of dual
therapy with one of the following agents: DPP-4
inhibitors, pioglitazone, SUs or SGLT-2 inhibitors [4, 6].
The choice of second-line agent should be based upon
patient-specific considerations to minimise side effects
whilst reducing HbA1c levels [7].
Established agents such as SUs are highly efficacious
but are associated with weight gain and may cause
hypoglycaemia [8]. TZDs do not induce hypoglycaemia,
but tend to cause weight gain and fluid retention, and
have been associated with an increased risk of heart
failure [6, 9]. Unlike SUs and TZDs, DPP-4 inhibitors
do not lead to weight gain and a have minimal risk
for hypoglycaemia, comparable to metformin [10, 11].
Likewise, SGLT-2 inhibitors do not induce hypoglycaemia
and bring the added benefits of reductions in body weight
and blood pressure [12–14]. Results from the EMPA-REG
OUTCOME [15] and CANVAS [16] randomised con-
trolled trials and the CVD-REAL observational studies
[17–19] have shown a reduced risk for major adverse
cardiovascular events, hospitalisation for heart failure or
death in patients with T2D treated with SGLT-2 inhibitors,
with additional studies ongoing [20]. GLP-1 receptor ago-
nists are associated with low risk for hypoglycaemia and
significant reductions in body weight [21]. GLP-1 receptor
agonists are not generally recommended as a second-line
therapy in the UK [22], and their effect on adverse cardio-
vascular outcomes is inconsistent. While liraglutide has
been associated with a reduction in adverse cardiovascular
outcomes in patients with T2D at high cardiovascular risk,
a neutral effect on cardiovascular outcomes has been
observed with other GLP-1 receptor agonists [23–26].
Of all the glucose-lowering agents, insulin has the
greatest HbA1c-lowering potential, although it carries
the highest risk of hypoglycaemia and is associated
with weight gain [6, 21].
The NICE guidelines and the position statement of the
American Diabetes Association and the European
Association for the Study of Diabetes recommend that
therapies should be reviewed every 3–6 months, and
therapy escalated if HbA1c targets are not met. Despite
these recommendations, therapeutic inertia is still com-
mon, with the average time to initiate second-line ther-
apy in the UK being between 1.6 to 2.9 years after
HbA1c levels had reached those recommended for treat-
ment intensification (HbA1c > 7.5% [58 mmol/mol])
[27]. Likewise, in patients from North America, Europe
and Israel receiving one oral anti-diabetic drug,
second-line treatment intensification occurs a median of
0.3–2.7 years following above-target HbA1c levels [28].
This may carry grave consequences for patients who
have poor glycaemic control for extended periods and
may result in higher risk of cardiovascular events and
other late-stage diabetes complications [29]. On the
other hand, patients who receive earlier treatment
intensification have greater HbA1c reductions and a
higher probability of attaining target HbA1c levels, as
well as a lower risk of micro- and macrovascular
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complications, compared with patients with delayed
intensification [2, 3, 30–32].
Real-world clinical-practice data are an important source
of evidence for clinicians considering second-line therapies
for the treatment of T2D. This study assessed the clinical
outcomes of patients initiated on second-line glucose-low-
ering therapies, using data from the UK Clinical Practice
Research Datalink (CPRD). The impact of these
second-line therapies on HbA1c, weight and treatment per-
sistence was evaluated over 18 months in patients who had
received first-line metformin monotherapy. The data in this
manuscript were accepted as an abstract for - and pre-
sented at - the 53rd Annual Meeting of the European Asso-
ciation for the Study of Diabetes [33].
Methods
Data source
This retrospective study was performed using data retrieved
from the UK CPRD, which contains anonymised longitu-
dinal primary-care medical records from over 14 million
patients and is broadly representative of the UK population
[34]. The study protocol was approved by the independent
scientific advisory committee of the UK CPRD (protocol
16_045R).
Study population
The cohort comprised patients with T2D aged ≥ 18 years
who initiated a second-line therapy between 1 August
2013 and 14 June 2016. Only patients who received met-
formin monotherapy as first-line therapy were included in
the analysis, irrespective of the duration of metformin
treatment before initiation of second-line therapy and
HbA1c values at the time of treatment initiation. Patients
were grouped according to second-line therapy, which
could include any glucose-lowering medication, oral or in-
jectable, given either as an add-on to metformin or as a
switch to a single agent or in combination with other
agents after discontinuing metformin. For this analysis,
patients were stratified into one of the following groups:
metformin in combination with an SU (glibenclamide,
glipizide, gliclazide, glimepiride, tolbutamide or chlorprop-
amide), metformin in combination with a DPP-4 inhibitor
(sitagliptin, vildagliptin, saxagliptin, linagliptin or alogliptin),
metformin in combination with an SGLT-2 inhibitor (cana-
gliflozin, dapagliflozin or empagliflozin), or metformin in
combination with any other second-line therapy (including
pioglitazone, a GLP-1 receptor agonist, an insulin, repagli-
nide, natiglinide, acarbose) or another second-line therapy
following metformin discontinuation.
Study design
This was an observational study comparing the use of
second-line glucose-lowering agents in patients with
T2D who received metformin as their first-line therapy.
The index date was the date of second-line therapy initi-
ation, and baseline measurements of HbA1c and weight
closest to the index date (within 180 days prior to the
index date and 2 weeks after the index date) were se-
lected for analysis. The follow-up periods were defined
as 6, 12 and 18 months, with measurements closest to
each time point (±90 days) selected for the analysis. To
represent an on-treatment population, data were ana-
lysed for patients who were receiving their index
second-line treatment at each time point (i.e. had not
intensified, switched or discontinued treatment) and
who had data available for the variable of interest
(HbA1c or weight) at baseline and the time point being
analysed. Discontinuation of second-line therapy was de-
fined as cessation of treatment for 184 days or more.
Study outcomes
Index treatment persistence over the 18-month study
period was evaluated. HbA1c and weight were evaluated
for all patients who were on-treatment and had data
available at both baseline and the end of the correspond-
ing follow-up period. A composite outcome assessed
treatment success, defined as the number of patients
who had not discontinued their index therapy, achieved
HbA1c reductions ≥ 0.5% (5.5 mmol/mol) and weight re-
ductions ≥ 2 kg at 18 months. The individual compo-
nents of the composite endpoint were also evaluated for
all patients who had HbA1c and weight data available at
baseline and at 18 months.
Statistical analysis
The characteristics of the study population were sum-
marised with descriptive statistics (number, mean, stand-
ard deviation [SD], standard error [SE], median and
interquartile range [IQR]). Demographics and baseline
characteristics, as well as changes in HbA1c and weight
over time, are presented separately for the different
second-line treatment groups. Mean (SE) HbA1c and
weight at baseline and at the 6-, 12- and 18-month time
points were used to calculate crude changes over each
6-month period. For each second-line therapy group, the
change in HbA1c and weight at each time point was
determined using analysis of covariance (ANCOVA)
models, adjusted for baseline measurements using
variance-weighted least-squares regression estimation.
The relationship between baseline measurements and
the changes at each subsequent time point was explored
to determine the best way to adjust for baseline mea-
surements. The relationship between baseline HbA1c
and change in HbA1c was not strictly linear and was
modelled using linear splines as two straight lines con-
nected at a baseline HbA1c of 9% (75 mmol/mol) [28].
The relationship between baseline body mass index
(BMI) and change in BMI showed no evidence of
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departure from linearity and was, therefore, modelled in
a linear manner.
The composite outcome (number [%] of patients who
had not discontinued index therapy, achieved HbA1c
reductions of ≥ 0.5% [5.5 mmol/mol] and weight
reductions of ≥ 2 kg at 18 months) was tabulated by
second-line treatment type.
Results
Patient populations
From the initial 407,700 patients screened, we identified
9097 patients with T2D who had received first-line met-
formin monotherapy and were initiated on second-line
treatment (Additional file 1: Figure S1). The median
(IQR) time between initiating metformin and initiating
second-line therapy was 2.3 (0.85–4.72) years. The most
common second-line treatments were metformin plus
an SU (n = 4655; 51.2%), metformin plus a DPP-4 inhibi-
tor (n = 2899; 31.9%) and metformin plus a SGLT-2 in-
hibitor (n = 441; 4.8%). The remaining 1102 patients
(12.1%) were on a variety of second-line treatments and
were combined into the other category. This included
monotherapy with an SU (n = 397; 4.4%), monotherapy
with a DPP-4 inhibitor (n = 212; 2.3%), monotherapy with
any other agent (n = 38; 0.4%), insulin either as mono- or
combination therapy (n = 46; 0.5%) or any other drug
combinations not specified above (n = 409; 4.5%).
The baseline characteristics of the patients included in
the analysis are shown in Table 1. Overall 57.2% of the
patients were male, their mean age was 61.2 years and
the mean HbA1c was 9.0% (75 mmol/mol). The baseline
characteristics varied among the groups, with higher
mean baseline HbA1c values observed for patients who
received metformin plus an SU or metformin plus an
SGLT-2 inhibitor, compared with patients who received
metformin plus a DPP-4 inhibitor or other therapies. Pa-
tients who were initiated on second-line therapy with an
SGLT-2 inhibitor had the highest mean BMI and body
weight values, with patients who were initiated on
second-line therapy with a DPP-4 inhibitor having the
second highest values. Furthermore, patients who were
initiated on second-line treatment with an SGLT-2
inhibitor were younger and had the shortest duration
between initiation of metformin and initiation of
second-line therapy. Patients in the other therapy group
had the longest interval between initiation of first- and
second-line therapies.
Persistence of second-line treatment
The proportion of patients who changed or discontinued
their index second-line therapy over the 18-month
follow-up period for each treatment group is shown in
Fig. 1. Overall, the cumulative proportion changing
therapy (including discontinuation, switch or intensification)
was 21.6%, 34.8% and 47.3% at 6, 12 and 18 months of
follow-up, respectively.
Across all time points, fewer patients receiving metfor-
min plus an SGLT-2 inhibitor changed therapy, with
42.3% cumulative proportion of patients changing treat-
ment by 18 months. For patients receiving metformin
plus either an SU or a DPP-4 inhibitor, the cumulative
proportion of patients changing treatment for both ther-
apies was 46.8%. Patients receiving other regimens chan-
ged treatment most frequently, with 52.8% cumulative
proportion of patients changing treatment at 18 months,
a significantly higher incidence compared with that seen
in patients receiving metformin plus either an SU or a
DPP-4 inhibitor (p = 0.003).
Changes in HbA1c
For all patients initiated on second-line therapy (including
those who subsequently discontinued, switched or
intensified treatment), the mean unadjusted changes in
HbA1c were −1.26% (−13.8 mmol/mol; n = 6042), −1.16%
(−12.7 mmol/mol; n = 4945) and −0.99% (−10.8 mmol/mol;
n = 3665) at 6, 12 and 18 months, respectively. When only
patients who were on-treatment (i.e. had not intensified,
switched or discontinued second-line treatment) were in-
cluded in the analysis, the mean unadjusted changes in
HbA1c were −1.38% (−15.1 mmol/mol; n = 4480), −1.32%
(−14.4 mmol/mol; n = 3080) and − 1.20% (−13.1 mmol/mol;
n = 1755) at 6, 12 and 18 months, respectively.
Analysis of HbA1c levels at 6 months shows that pa-
tients with lower baseline HbA1c levels experienced
smaller changes from baseline, and fewer achieved
HbA1c reductions ≥ 0.5% (5.5 mmol/mol) compared
with patients with a higher baseline HbA1c (Table 2).
The change in HbA1c levels at 6 and 18 months
correlated with baseline HbA1c levels, and the changes
were more marked in patients with baseline HbA1c
levels ≥ 9.0% (75 mmol/mol; p < 0.001; Fig. 2). At
6 months, patients who had baseline HbA1c levels < 9.0%
(75 mmol/mol), had an expected additional HbA1c
decrease of 0.48% (5.2 mmol/mol) for every 1.0%
(10.9 mmol/mol) increment in baseline HbA1c, whereas
patients with baseline HbA1c levels ≥ 9.0% had an expected
additional HbA1c decrease of 0.75% (8.2 mmol/mol) for
every 1.0% increment. This correlation was maintained
throughout the 18 months of therapy (p = 0.015).
The mean changes in HbA1c over 18 months, after ad-
justment for baseline values for each second-line treatment
group, are shown in Table 3. At 6 months, patients receiv-
ing metformin plus an SU or metformin plus an SGLT-2
inhibitor had the greatest mean reductions in HbA1c
(−1.33% [−14.5 mmol/mol] and − 1.26% [−13.8 mmol/mol],
respectively), and, combined, these reductions were signifi-
cantly greater (p < 0.001) than those observed in patients re-
ceiving metformin plus a DPP-4 inhibitor or other therapies
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Table 1 Demographic and baseline characteristics
MET + SU
N = 4655
MET + DPP-4i
N = 2899
MET + SGLT-2i
N = 441
Other*
N = 1102
Overall
N = 9097
Male, n (%) 2679 (57.6) 1704 (58.8) 266 (60.3) 551 (50.0) 5200 (57.2)
Age (years), mean (SD) 61.54 (12.97) 60.81 (12.34) 55.05 (10.14) 62.81 (14.85) 61.15 (12.98)
<50 892 (19.2%) 544 (18.8%) 128 (29.0%) 210 (19.1%) 1774 (19.5%)
50 to <60 1150 (24.7%) 805 (27.8%) 165 (37.4%) 241 (21.9%) 2361 (26.0%)
60 to <70 1291 (27.7%) 842 (29.0%) 119 (27.0%) 275 (25.0%) 2527 (27.8%)
≥70 1322 (28.4%) 708 (24.4%) 29 (6.6%) 376 (34.1%) 2435 (26.8%)
HbA1c (%), mean (SD) 9.19 (1.88) 8.75 (1.50) 9.07 (1.58) 8.72 (1.91) 8.98 (1.77)†
<7 283 (6.2%) 147 (5.1%) 20 (4.6%) 164 (15.2%) 614 (6.9%)
7 to <8 971 (21.3%) 829 (28.8%) 100 (23.0%) 276 (25.5%) 2176 (24.3%)
8 to <9 1245 (27.3%) 923 (32.1%) 120 (27.7%) 254 (23.5%) 2542 (28.4%)
9 to <10 783 (17.2%) 468 (16.3%) 84 (19.4%) 152 (14.1%) 1487 (16.6%)
10 to <11 491 (10.8%) 244 (8.5%) 54 (12.4%) 92 (8.5%) 881 (9.8%)
≥11 787 (17.3%) 266 (9.3%) 56 (12.9%) 144 (13.3%) 1253 (14.0%)
HbA1c (mmol/mol), mean (SD) 77 (20.6) 72 (16.4) 76 (17.3) 72 (20.9) 75 (19.3)†
BMI (kg/m2, mean (SD) 31.78 (6.50) 33.21 (6.56) 36.56 (6.98) 33.12 (7.93) 32.64 (6.82)†
<20 43 (0.9%) 8 (0.3%) 0 24 (2.2%) 75 (0.8%)
20 to <25 498 (10.9%) 194 (6.8%) 8 (1.8%) 106 (9.8%) 806 (9.0%)
25 to <30 1457 (31.9%) 795 (27.7%) 65 (14.8%) 273 (25.2%) 2590 (28.9%)
30 to <35 1366 (29.9%) 887 (31.0%) 129 (29.5%) 301 (27.8%) 2683 (30.0%)
≥35 1208 (26.4%) 982 (34.3%) 236 (53.9%) 379 (35.0%) 2805 (31.3%)
Weight (kg), mean (SD) 90.97 (21.00) 96.00 (21.50) 107.30 (22.87) 93.63 (25.55) 93.70 (22.18)†
<60 189 (4.1%) 63 (2.2%) 2 (0.5%) 51 (4.7%) 305 (3.4%)
60 to <80 1227 (26.6%) 578 (20.1%) 40 (9.1%) 298 (27.3%) 2143 (23.8%)
80 to <100 1837 (39.9%) 1133 (39.3%) 127 (28.9%) 361 (33.1%) 3458 (38.4%)
100 to <120 954 (20.7%) 728 (25.3%) 166 (37.7%) 232 (21.3%) 2080 (23.1%)
≥120 399 (8.7%) 378 (13.1%) 105 (23.9%) 149 (13.7%) 1031 (11.4%)
Time since diagnosis (years), median (IQR) 4.00 (1.57–7.20) 4.25 (1.88–7.21) 3.30 (1.47–5.55) 4.64 (1.94–8.05) 4.10 (1.70–7.22)
<6 months 542 (11.6%) 237 (8.2%) 40 (9.1%) 74 (6.7%) 893 (9.8%)
6 months to <1 year 283 (6.1%) 174 (6.0%) 35 (7.9%) 68 (6.2%) 560 (6.2%)
1 to <3 years 1076 (23.1%) 658 (22.7%) 129 (29.3%) 250 (22.7%) 2113 (23.2%)
3 to <5 years 839 (18.0%) 591 (20.4%) 104 (23.6%) 194 (17.6%) 1728 (19.0%)
≥5 years 1915 (41.1%) 1239 (42.7%) 133 (30.2%) 516 (46.8%) 3803 (41.8%)
Time since initiation of first-line therapy
(years), median (IQR)
2.20 (0.72–4.65) 2.62 (1.02–4.89) 2.05 (0.85–4.02) 2.30 (0.89–4.84) 2.33 (0.85–4.72)
<6 months 953 (20.5%) 427 (14.7%) 71 (16.1%) 171 (15.5%) 1622 (17.8%)
6 months to <1 year 474 (10.2%) 280 (9.7%) 50 (11.3%) 124 (11.3%) 928 (10.2%)
1 to <3 years 1346 (28.9%) 884 (30.5%) 157 (35.6%) 346 (31.4%) 2733 (30.0%)
3 to <5 years 840 (18.1%) 613 (21.2%) 89 (20.2%) 199 (18.1%) 1741 (19.1%)
≥5 years 1042 (22.4%) 695 (24.0%) 74 (16.8%) 262 (23.8%) 2073 (22.8%)
BMI body mass index, DPP-4i dipeptidyl peptidase-4 inhibitor, HbA1c glycated haemoglobin, IQR interquartile range, MET metformin, SD standard deviation,
SGLT-2i sodium–glucose cotransporter 2 inhibitor, SU sulfonylurea
*Includes all other add-on combinations to metformin, combinations without metformin and other monotherapies
†Baseline HbA1c, BMI and weight were missing for 144, 138 and 80 patients, respectively
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(−1.11% [−12.1 mmol/mol] and− 1.03% [−11.3 mmol/mol],
respectively). At 18 months, there was a trend for patients
receiving metformin plus an SGLT-2 inhibitor to achieve
greater mean reductions in HbA1c, compared with patients
receiving any other treatment (−1.46% [−16 mmol/mol]
versus −1.21% [−13.2 mmol/mol]; p = 0.052; Table 3).
Changes in weight
In all four treatment groups, weight loss from baseline
at 18 months was directly correlated with baseline
weight (Additional file 2: Figure S2). The mean
baseline-adjusted changes in weight at 6, 12 and
18 months for each treatment group are shown in Fig. 3.
The greatest mean reduction in weight from baseline
was observed for patients who received metformin plus
an SGLT-2 inhibitor (mean weight loss at 18 months,
4.2 kg; p < 0.001 versus baseline). A significant mean re-
duction in weight from baseline was also observed for
patients receiving metformin plus a DPP-4 inhibitor
(mean weight loss at 18 months, 1.5 kg; p < 0.001 versus
baseline). In contrast, small but significant mean increases
in weight from baseline (p < 0.001) were observed at all
time points for patients receiving metformin plus an SU.
Overall, no pattern of weight change was observed for pa-
tients receiving other second-line treatments.
Achievement of the composite outcome of treatment
success according to second-line therapy
To evaluate treatment success, a composite outcome,
defined as the number of patients who had not discon-
tinued their index therapy, achieved HbA1c reductions
≥0.5% (5.5 mmol/mol) and weight reductions ≥ 2 kg at
18 months, was assessed for all patients with data avail-
able at baseline and 18 months (Table 4). A higher pro-
portion of patients assigned to the metformin plus an
SGLT-2 inhibitor treatment group achieved HbA1c re-
ductions ≥0.5% (71.6%) or weight reductions ≥ 2.0 kg
(71.6%) at 18 months, compared with all the other treat-
ment groups analysed. Of patients who intensified met-
formin treatment with a DPP-4 inhibitor, 55.1% achieved
HbA1c reductions ≥ 0.5% and 42.8% of patients had
weight reductions ≥ 2.0 kg. By comparison, 66% of pa-
tients on metformin plus an SU group achieved HbA1c
reductions ≥ 0.5%, although only 25.6% achieved weight
loss ≥ 2.0 kg at 18 months. Treatment persistence at
18 months was highest for patients receiving metformin
plus an SU (56.4%) and metformin plus an SGLT-2 in-
hibitor (55.4%).
Overall, 36.5% of patients receiving metformin plus an
SGLT-2 inhibitor met the composite outcome for treat-
ment success, compared with 17.1% of those who re-
ceived metformin plus a DPP-4 inhibitor, 9.6% of those
who received metformin plus an SU and 9.1% of patients
who received other treatments. This pattern was
confirmed after adjustment for baseline HbA1c, weight,
age, sex and time since initiation of first-line treatment.
Multivariate analysis showed that initiation of second-
line therapy with an SGLT-2 inhibitor resulted in a sig-
nificantly higher overall success rate, compared with all
other second-line therapies combined (p < 0.001).
Fig. 1 Cumulative proportion of patients changing second-line
therapy over time according to treatment group. Frequency is
shown as proportion of 1. DPP-4i dipeptidyl peptidase-4 inhibitor,
MET metformin, SGLT-2i sodium–glucose cotransporter 2 inhibitor,
SU sulfonylurea. *Includes all other add-on combinations to metformin,
combinations without metformin and other monotherapies
Table 2 Change in HbA1c at 6 months post-initiation of second-line treatment, stratified by baseline HbA1c category
Baseline HbA1c N Mean change at 6 months (standard error) N (%) with fall
≥ 0.5% at
6 months
% mmol/mol % mmol/mol
<7.5 < 58 811 0.02 (0.04) 0.2 (0.4) 277 (34.2)
7.5 to <9.0 58 to <75 2751 −0.71 (0.02) −7.8 (0.2) 1855 (67.4)
9.0 to <10.5 75 to <91 1325 −1.47 (0.04) −16.1 (0.4) 1099 (82.9)
10.5 to <12.0 91 to <108 715 −2.48 (0.06) −27.1 (0.7) 641 (89.7)
≥12.0 ≥108 440 −4.40 (0.12) −48.1 (1.3) 405 (92.1)
Overall 6042 −1.26 (0.02) −13.8 (0.2) 4277 (70.8)
Data from patients who had available HbA1c measurements at 6 months and at baseline, and who were on-treatment at 6 months (i.e. had not switched,
intensified or discontinued second-line treatment since the previous time point)
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Discussion
This study used a large, representative population of UK
patients to evaluate the use of second-line therapies
after metformin monotherapy in a real-world clinical
practice setting.
Unlike most clinical trials, which have durations of
6–12 months, this observational study followed patients
for 18 months, with 6-month follow-up intervals, and
compared the effect of initiation of different second-line
therapies on three clinically relevant criteria: changes in
HbA1c and weight, and treatment persistence. When
these three criteria were evaluated as a composite out-
come representative of treatment success at 18 months,
more patients (36.5%) on metformin plus an SGLT-2 inhibi-
tor achieved HbA1c reductions of ≥ 0.5% (5.5 mmol/mol),
body weight loss ≥ 2 kg and treatment persistence for
18 months, compared with all other therapies. Patients who
received combination therapy with metformin plus a
DPP-4 inhibitor achieved the second highest compos-
ite outcome, with 17.1% of patients achieving treat-
ment success.
In this study, all second-line therapies reduced HbA1c
levels, with a mean reduction of 1.2% (13.4 mmol/mol)
at 18 months. HbA1c reductions achieved at 6 months
following second-line treatment initiation correlated
with HbA1c levels at baseline: patients with lower base-
line levels experience smaller HbA1c reductions than pa-
tients who had higher baseline levels. This observation is
in line with previous studies, which report a positive cor-
relation between baseline HbA1c and subsequent
changes in HbA1c levels [28, 35]. The greatest reduc-
tions in HbA1c at 6 months were observed in patients
on metformin plus an SU or on metformin plus an
SGLT-2 inhibitor, although at 18 months, these reduc-
tions were observed only in patients on metformin plus
an SGLT-2 inhibitor. It is known that SUs are highly
Fig. 2 Relationship between change in HbA1c and baseline HbA1c (patient-level data). Scatter plots of baseline (index) HbA1c against change in
HbA1c at a 6 and b 18 months. Regression lines are shown as grey dashed lines, and their corresponding gradient slopes (m) were calculated for
baseline HbA1c levels < 9% and ≥ 9%. SE standard error
Table 3 Change in HbA1c levels over 18 months after initiation of second-line treatment
Second-line
treatment
6 months 12 months 18 months
N (%) Mean change in HbA1c (SE)* N (%) Mean change in HbA1c (SE)* N (%) Mean change in HbA1c (SE)*
% mmol/mol % mmol/mol % mmol/mol
MET + SU 2257 (50.38) −1.33 (0.04) −14.5 (0.4) 1571 (51.01) −1.30 (0.04) −14.2 (0.4) 907 (51.68) −1.21 (0.05) −13.2 (0.5)
MET + DPP-4i 1486 (33.17) −1.11 (0.04) −12.1 (0.4) 1044 (33.90) −1.12 (0.05) −12.2 (0.5) 572 (32.59) −1.23 (0.06) −13.4 (0.7)
MET + SGLT-2i 225 (5.02) −1.26 (0.08) −13.8 (0.9) 156 (5.06) −1.32 (0.10) −14.4 (1.1) 90 (5.13) −1.46 (0.13) −16.0 (1.4)
Other† 512 (11.43) −1.03 (0.06) −11.3 (0.7) 309 (10.03) −1.20 (0.08) −13.1 (0.9) 186 (10.60) −1.18 (0.10) −12.9 (1.1)
Overall 4480 −1.23 (0.03) −13.4 (0.3) 3080 −1.24 (0.04) −13.6 (0.4) 1755 −1.23 (0.05) −13.4 (0.5)
Data from patients who had available HbA1c measurements at each time point and at baseline, and who were on-treatment at each time point (i.e. had not
switched, intensified or discontinued second-line treatment since the previous time point)
*Baseline adjusted means using analysis of covariance
†Includes all other add-on combinations to metformin, combinations without metformin and other monotherapies
DPP-4i dipeptidyl peptidase-4 inhibitor, MET metformin, SGLT-2i sodium–glucose cotransporter 2 inhibitor, SE standard error, SU sulfonylurea
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efficient at rapidly reducing HbA1c levels in patients
with T2D, with only insulin acting on HbA1c faster [6].
However, many clinical trials comparing SU to other
therapies have shown the effects of SUs on HbA1c to be
short-lived [36–38]. The sustained reduction in HbA1c
levels observed in patients receiving metformin plus an
SGLT-2 inhibitor has been previously reported in a
meta-analysis [39]. However, the higher HbA1c levels at
baseline and the reduced number of patients who had
HbA1c measurements at 18 months in the CPRD data-
base may have contributed to the effect seen.
The effect of a particular treatment on weight is also
an important factor when deciding upon an appropriate
second-line agent, as obesity is often associated with
T2D [40]. Overall, modest weight gain was seen in pa-
tients who received the combination of metformin plus
an SU, whereas weight loss was observed for patients
treated with metformin plus either a DPP-4 inhibitor or
an SGLT-2 inhibitor, with significantly greater weight
loss observed in patients receiving an SGLT-2 inhibitor.
While DPP-4 inhibitors are generally considered to be
weight neutral [6], reductions in BMI following treat-
ment with a DPP-4 inhibitor have been observed in a
previous database analysis in Italy [41]. Weight reduc-
tions comparable to those reported here following
treatment with a DPP-4 inhibitor (mean −1.58 kg at
12 months) were also seen in a previous analysis of a US
database, in which patients achieved a mean weight
change from baseline of −1.26 kg at 12 months [42]. Pre-
vious studies have demonstrated the add-on benefit of
SGLT-2 inhibitors by promoting weight loss via in-
creased glucose excretion [43–46]. The weight reduc-
tions seen in this analysis following initiation with an
SGLT-2 inhibitor were higher than those observed in
clinical trials (mean weight reduction at 18 months of
4.2 kg versus 2.2–3.4 kg) [43] and continued at each
time point up to 18 months, which may reflect a greater
likelihood of treatment persistence in those who lose
weight. Patients who received an SGLT-2 inhibitor-based
treatment generally had a higher weight at baseline, sug-
gesting selection of this therapy in more obese patients
due to its established effects on weight, consistent with
NICE guidelines [4, 47]. Given the demonstrated correl-
ation between baseline weight and weight loss, this may
also partly account for the greater weight loss observed
with SGLT-2 inhibitors in this analysis. Additionally, the
low number of patients who had weight measurements
at 18 months in the SGLT-2 inhibitors group could be
considered a possible confounder. Perhaps expectedly,
no overall change in weight was observed in patients in-
cluded in the other group, as this group included both
Fig. 3 Baseline-adjusted change in weight over 18 months in
patients initiated on second-line therapies. Data are means ± SE.
Data are from patients who had available weight measurements at
each timepoint and at baseline, and who were on-treatment at each
time-point (i.e. had not switched, intensified or ceased second-line
treatment since the previous time-point). DPP-4i, dipeptidyl
peptidase-4 inhibitor; MET, metformin; N, number of patients; SGLT-
2i, sodium–glucose cotransporter 2 inhibitor; SE, standard error; SU,
sulfonylurea. *Includes all other add-on combinations to metformin,
combinations without metformin and other monotherapies
Table 4 Composite outcome representing treatment success after 18 months for each treatment group
Second-line treatment N HbA1c reduction ≥ 0.5%
(≥ 5.5 mmol/mol)
Weight-loss ≥ 2 kg No treatment change
over 18 months
Overall success (i.e. attained
all three endpoints)
MET + SU 847 559 (66.0) 217 (25.6) 478 (56.4) 81 (9.6)
MET + DPP-4i 608 335 (55.1) 260 (42.8) 300 (49.3) 104 (17.1)
MET + SGLT-2i 74 53 (71.6) 53 (71.6) 41 (55.4) 27 (36.5)
Other* 187 105 (56.2) 61 (32.6) 91 (48.7) 17 (9.1)
Overall 1716 1052 (61.3) 591 (34.4) 910 (53.0) 229 (13.3)
Data are in n (%). Data from all patients who had both HbA1c and weight measurements available at baseline and at 18 months
DPP-4i dipeptidyl peptidase-4 inhibitor, MET metformin, SGLT-2i sodium–glucose cotransporter 2 inhibitor, SU sulfonylurea
*Includes all other add-on combinations to metformin, combinations without metformin and other monotherapies
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patients who received agents that are known to cause
weight gain (including insulins and TZDs) and patients
who received agents associated with weight loss (includ-
ing GLP-1 receptor agonists). The weight changes pre-
sented in this analysis were adjusted for baseline values
to allow comparisons between treatment groups. How-
ever, the effect of second-line treatment on weight has
been associated with ethnicity, with Asian populations
showing a greater response to agents such as DPP-4 in-
hibitors [48]. Despite information on ethnic groups not
being available in the CPRD, the Asian population in the
UK represents approximately 7% of the general popula-
tion [49] and, thus, this population effect should not be
considered a potential bias.
A pooled analysis of previous clinical and observa-
tional studies reported that treatment persistence in pa-
tients with T2D receiving oral anti-diabetic agents
ranged from 41.0 to 81.1%, and treatment discontinu-
ation estimates ranged from 9.9% to 60.1% [50]. In the
current study, treatment persistence was highest in
patients receiving treatment with metformin plus an
SGLT-2 inhibitor at all time points, with 57.7% of pa-
tients continuing with the index treatment at 18 months.
By comparison, 53.2% of patients who received metfor-
min plus either an SU or a DPP-4 inhibitor and 47.2% of
patients on other treatments continued with their index
therapies, respectively. In line with this, a previous study
has shown greater treatment persistence in patients re-
ceiving SGLT-2 inhibitors versus SU [51]. The higher
rates of treatment persistence seen with an SGLT-2
inhibitor may be associated with the steady decrease in
HbA1c levels and weight reductions and reflect
increased patient satisfaction with these therapies.
Although the reasons for patient discontinuation,
switching or intensification of therapy were not reliably
recorded in the UK CPRD, and information on adher-
ence to medication and completion of each course of
treatment were limited to the available records, in clin-
ical practice common reasons for discontinuation or
change of treatment include undesirable side effects
(such as weight gain or risk of hypoglycaemia) and inef-
ficacy of treatment requiring intensification or change of
therapy [52].
The median time to initiation of second-line treatment
did not differ substantially among the different treat-
ment groups investigated, with patients initiating
second-line therapy a median of 2.3 years after metfor-
min initiation. Therapeutic inertia remains an issue in
clinical practice, with a previous analysis of the UK
CPRD database observing a delay of 1.6–2.9 years before
second-line treatment intensification in patients with sub-
optimal glycaemic control (study cohort of 81,573 pa-
tients) [27]. Another analysis of the UK CPRD (n = 6710)
observed that only 39.5% of patients had their treatment
intensified within the year following metformin monother-
apy treatment failure (HbA1c ≥ 7% [53 mmol/mol]), and
24% of patients had no evidence of treatment in-
tensification throughout the ~4.3 years of the study
[31]. In an analysis of a large US insurance claims data-
base (n = 11,525), which included a cohort of patients with
T2D and poor glycaemic control (HbA1c ≥ 8% [64 mmol/
mol]), more than half (52%) of the patients did not receive
treatment intensification within 12 months of treatment
failure [53]. Another study using a US claims database that
included patients with T2D identified a mean time to
treatment intensification after HbA1c levels were above
the target of over 700 days [54]. A recent systematic re-
view that assessed data from patients with T2D from
North America, Europe and Israel showed that the median
time to treatment intensification after HbA1c levels were
above target was 0.3–2.7 years and 1.3–4.9 years, in patients
receiving one or two oral anti-diabetic drugs respectively
[28].
As an observational study, this analysis had a number
of limitations. Firstly, as it aimed to represent a popula-
tion on-treatment, patients at each time point who dis-
continued, switched or intensified the index second-line
treatment, as well as those who did not have HbA1c
levels or body weight data available, were censored from
the study. The number of patients evaluated for changes
in HbA1c levels and weight were, therefore, smaller at
later time points. This is particularly noticeable for the
analysis at 18 months, which may limit the generalisabil-
ity of the results. Secondly, only patients whose first-line
therapy was metformin monotherapy were included. Al-
though these patients accounted for the majority of
those identified initiating a second-line therapy in the
CPRD, consistent with guidelines and clinical practice
[4, 6], this patient population may limit the generalisabil-
ity of these findings to patients who receive a different
first-line therapy. Thirdly, consideration should be given
to the limited use of some of the more recent
glucose-lowering therapies, such as DPP-4 inhibitors
and SGLT-2 inhibitors, which have not been used as
widely, as is the case for older, more established therap-
ies. Moreover, these more recent therapies were not
recommended by NICE guidelines as a treatment choice
for treatment intensification after metformin until
December 2015, close to the cut-off date for inclusion in
this study. Consequently, fewer patients were exposed to
these agents, limiting the analyses and interpretations of
these results. And fourthly, given the low number of pa-
tients identified who received therapy combinations
other than metformin plus an SU, a DPP-4 inhibitor or an
SGLT-2 inhibitor or received second-line therapy without
metformin, these patients were combined into the other
treatment group, which prevented reliable analysis of clin-
ical outcomes for each individual treatment strategies.
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In addition to the above, observational studies using
databases such as the UK CPRD inherently have a num-
ber of limitations, including potential issues relating to
the quality of the data for key clinical measurements and
possible misclassification of exposure and outcome.
Hypoglycaemia events were not reliably captured in the
UK CPRD, which prevents the assessment of risk of
hypoglycaemia for second-line therapy in this analysis.
The reports for events such as diabetic ketoacidosis or
urinary tract infections are also limited and, therefore,
not reported in this analysis. These safety events have
been formally evaluated in other post-authorisation
safety studies specifically designed to that end, and their
incidence evaluated in an independent meta-analysis
[55] and in clinical practice [56]. In addition, there is the
possibility of confounding by indication, as patients were
not randomised to receive the treatments; rather, treat-
ments were selected by the physician based on clinical
judgement according to specific patient characteristics.
This non-random selection resulted in the differences
between the baseline characteristics of the treatment
groups. While multivariate regression was undertaken to
adjust for the measured differences, the possibility of re-
sidual confounding contributing to the findings remains.
Conclusions
In this population-based cohort, all second-line therapies
initiated after metformin monotherapy improved gly-
caemic control, with the greatest HbA1c reductions seen
in patients with higher baseline HbA1c levels. In
addition, significant reductions in weight were observed
for patients treated with metformin plus either a DPP-4
inhibitor or an SGLT-2 inhibitor. The lowest incidence
of second-line therapy change was seen in patients
treated with metformin plus an SGLT-2 inhibitor. Pa-
tients treated with metformin plus an SGLT-2 inhibitor
were most likely to achieve a composite of HbA1c re-
duction ≥ 0.5% (5.5 mmol/mol), weight reduction ≥ 2 kg
and continued treatment at 18 months. This highlights
the potential benefits of treating patients with more re-
cent agents, including SGLT-2 inhibitors. The ongoing,
randomised, pragmatic trial (DECIDE; NCT02616666)
aims to evaluate the comparative effectiveness between
the SGLT-2 inhibitor dapagliflozin and standard of care
over 2 years in patients with T2D, and should provide
further data on this therapeutic class [57].
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